Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gilles Toumaniantz
The Sodium–Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Diabetes
Internal Medicine
Endocrinology
Metabolism
Diabetes
RhoA Phosphorylation Induces Rac1 Release From Guanine Dissociation Inhibitor and Stimulation of Vascular Smooth Muscle Cell Migration
Molecular and Cellular Biology
Cell Biology
Molecular Biology
Related publications
Sodium Glucose Cotransporter-2 (SGLT-2) Inhibitor Related Diabetic Ketoacidosis
European Scientific Journal ESJ
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, With Dapagliflozin and Ipragliflozin
Pharmaceutics
Pharmaceutical Science
Protective Effects of Ipragliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on a Non-Alcoholic Steatohepatitis Mouse Model
Yonago Acta Medica
Medicine
Clinical Risk Factors Predicting Genital Fungal Infections With Sodium–glucose Cotransporter 2 Inhibitor Treatment: The ABCD Nationwide Dapagliflozin Audit
Primary Care Diabetes
Internal Medicine
Nutrition
Endocrinology
Dietetics
Metabolism
Diabetes
Ertugliflozin: A Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitor for Glycemic Control in Type 2 Diabetes
Therapeutics and Clinical Risk Management
Euglycemic Diabetic Ketoacidosis Induced by Empagliflozin, Sodium-Glucose Cotransporter-2 Inhibitor, in Patient With Diabetes Mellitus Type 2 After Thoracic Surgery
Lijecnicki Vjesnik
Medicine
Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
Journal of Investigative Medicine High Impact Case Reports
Risk
Epidemiology
Reliability
Safety
Safety Research
Quality
Cardiovascular Effects of Sodium Glucose Cotransporter 2 Inhibitors
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Internal Medicine
Pharmacology
The Sodium Glucose Cotransporter 2 Inhibitor Empagliflozin Does Not Prolong QT Interval in a Thorough QT (TQT) Study
Cardiovascular Diabetology
Internal Medicine
Cardiology
Endocrinology
Cardiovascular Medicine
Metabolism
Diabetes
